Indivior outlines 30% adjusted EBITDA growth target for 2026 with new $400M share repurchase program
Indivior Pharmaceuticals, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $34.88
-4.4% in 7d after detection
Post-detection moves
1h
—
1d
+2.6%
3d
-0.2%
7d
-4.4%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS